These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 9314130)

  • 1. Analysis of the cost of population screening for haemochromatosis using biochemical and genetic markers.
    Bassett ML; Leggett BA; Halliday JW; Webb S; Powell LW
    J Hepatol; 1997 Sep; 27(3):517-24. PubMed ID: 9314130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decision analysis model for diagnostic strategies using DNA testing for hereditary haemochromatosis in at risk populations.
    Cooper K; Bryant J; Picot J; Clegg A; Roderick PR; Rosenberg WM; Patch C
    QJM; 2008 Aug; 101(8):631-41. PubMed ID: 18522976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Automated measurement of unsaturated iron binding capacity is an effective screening strategy for C282Y homozygous haemochromatosis.
    Hickman PE; Hourigan LF; Powell LW; Cordingley F; Dimeski G; Ormiston B; Shaw J; Ferguson W; Johnson M; Ascough J; McDonell K; Pink A; Crawford DH
    Gut; 2000 Mar; 46(3):405-9. PubMed ID: 10673305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic strategies using DNA testing for hereditary haemochromatosis in at-risk populations: a systematic review and economic evaluation.
    Bryant J; Cooper K; Picot J; Clegg A; Roderick P; Rosenberg W; Patch C
    Health Technol Assess; 2009 Apr; 13(23):iii, ix-xi, 1-126. PubMed ID: 19406046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for genetic haemochromatosis in blood samples with raised alanine aminotransferase.
    Bhavnani M; Lloyd D; Bhattacharyya A; Marples J; Elton P; Worwood M
    Gut; 2000 May; 46(5):707-10. PubMed ID: 10764716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-Effectiveness of Different Population Screening Strategies for Hereditary Haemochromatosis in Australia.
    de Graaff B; Neil A; Si L; Yee KC; Sanderson K; Gurrin L; Palmer AJ
    Appl Health Econ Health Policy; 2017 Aug; 15(4):521-534. PubMed ID: 28035629
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population screening for HFE-associated haemochromatosis: should we have to pay for our genes?
    Yapp TR; Eijkelkamp EJ; Powell LW
    Intern Med J; 2001; 31(1):48-52. PubMed ID: 11478357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of subjects with abnormal iron studies: role of the hepatic iron index.
    Chapman BA; Horton DM; Burt MJ; Romeril KR; Walmsley TA; Grant SJ; George P
    N Z Med J; 1994 Dec; 107(991):504-7. PubMed ID: 7830980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies for early diagnosis of haemochromatosis.
    Niederau C; Strohmeyer G
    Eur J Gastroenterol Hepatol; 2002 Mar; 14(3):217-21. PubMed ID: 11953684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for hemochromatosis: high prevalence and low morbidity in an unselected population of 65,238 persons.
    Asberg A; Hveem K; Thorstensen K; Ellekjter E; Kannelønning K; Fjøsne U; Halvorsen TB; Smethurst HB; Sagen E; Bjerve KS
    Scand J Gastroenterol; 2001 Oct; 36(10):1108-15. PubMed ID: 11589387
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The significance of haemochromatosis gene mutations in the general population: implications for screening.
    Burt MJ; George PM; Upton JD; Collett JA; Frampton CM; Chapman TM; Walmsley TA; Chapman BA
    Gut; 1998 Dec; 43(6):830-6. PubMed ID: 9824612
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preventing manifestations of hereditary haemochromatosis through population based screening.
    Haddow JE; Ledue TB
    J Med Screen; 1994 Jan; 1(1):16-21. PubMed ID: 8790482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population screening for haemochromatosis: expectations based on a study of relatives of symptomatic probands.
    Bradley LA; Haddow JE; Palomaki GE
    J Med Screen; 1996; 3(4):171-7. PubMed ID: 9041480
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population-based screening for hemochromatosis using phenotypic and DNA testing among employees of health maintenance organizations in Springfield, Missouri.
    McDonnell SM; Hover A; Gloe D; Ou CY; Cogswell ME; Grummer-Strawn L
    Am J Med; 1999 Jul; 107(1):30-7. PubMed ID: 10403350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epidemiology and diagnostic testing for hemochromatosis and iron overload.
    Adams PC
    Int J Lab Hematol; 2015 May; 37 Suppl 1():25-30. PubMed ID: 25976957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting the uptake of screening: a randomised controlled non-inferiority trial comparing a genotypic and a phenotypic strategy for screening for haemochromatosis.
    Patch C; Roderick P; Rosenberg W
    J Hepatol; 2005 Jul; 43(1):149-55. PubMed ID: 15876471
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening blood donors for hereditary hemochromatosis: decision analysis model comparing genotyping to phenotyping.
    Adams PC; Valberg LS
    Am J Gastroenterol; 1999 Jun; 94(6):1593-600. PubMed ID: 10364030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diagnosis and treatment of primary hemochromatosis].
    Swinkels DW; Marx JJ
    Ned Tijdschr Geneeskd; 1999 Jul; 143(27):1404-8. PubMed ID: 10422553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older.
    Baer DM; Simons JL; Staples RL; Rumore GJ; Morton CJ
    Am J Med; 1995 May; 98(5):464-8. PubMed ID: 7733125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of hereditary hemochromatosis in 16031 primary care patients.
    Phatak PD; Sham RL; Raubertas RF; Dunnigan K; O'Leary MT; Braggins C; Cappuccio JD
    Ann Intern Med; 1998 Dec; 129(11):954-61. PubMed ID: 9867748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.